Georgia's Online Cancer Information Center

Find A Treatment Site

Piedmont Columbus Regional

The John B. Amos Cancer Center is a multi-disciplinary cancer center accredited by the Commission on Cancer of the American College of Surgeons as a Community Hospital Comprehensive Cancer Program – the only treatment center to be so named in the 14-county service area of Columbus, Georgia. The center is also accredited by the American College of Radiology (ACR). The John B. Amos Cancer Center is a recipient of the Georgia Cancer Coalition Distinguished Cancer Scholars Award, which supports leaders who are engaged in the most promising areas of cancer research. John B. Amos is a member of the Atlanta Regional Community Clinical Oncology Program (ARCCOP), a program initiated by the National Cancer Institute (NCI) to provide community hospitals access to a wide range of clinical research studies. The center is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers and a member of the Georgia CORE Gynecologic Oncology Group Consortium. The center consists of eleven physicians with three clinics: medical oncology, gynecologic oncology and radiation oncology. The John B. Amos Cancer Center offers a medical team of experienced board-certified oncologists (MDs), advanced registered nurse practitioners, clinical researchers, case manager associates, clinical counselors, pharmacists, radiation physicists and therapists, oncology- and chemotherapy-certified nurses and registered dietitians.

Treatment Sites in Georgia

Clinical Trials in Georgia

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Cancer Type: Unknown Primary
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


A Randomized Phase II / III Trial of "Novel Therapeutics" versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial
Cancer Type: Myelodysplastic Syndromes (MDS)

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer

Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Cancer Type: Leukemia
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


EROS: Engendering Reproductive Health within Oncologic Survivorship
Cancer Type: Unknown Primary
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426
**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.
Georgia CORE

 

Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.